Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry-Reference-Cited by-同舟云学术

Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry

Published:2021-03-02 Issue:4 Volume:24 Page:926-936
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Alvarez-Manceñido Felipe^ORCID,Jimenez-Fonseca Paula,Carmona-Bayonas Alberto,Arrazubi Virginia,Hernandez Raquel,Cano Juana M.,Custodio Ana,Pericay Pijaume Carles,Aguado Gema,Martínez Lago Nieves,Sánchez Cánovas Manuel,Cacho Lavin Diego,Visa Laura,Martinez-Torron Alba,Arias-Martinez Aranzazu,López Flora,Limón M. Luisa,Vidal Tocino Rosario,Fernández Montes Ana,Alsina Maria,Pimentel Paola,Reguera Pablo,Martín Carnicero Alfonso,Ramchandani Avinash,Granja Mónica,Azkarate Aitor,Martín Richard Marta,Serra Olbia,Hernández Pérez Carolina,Hurtado Alicia,Gil-Negrete Aitziber,Sauri Tamara,Morales del Burgo Patricia,Gallego Javier

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10120-021-01169-6.pdf

Reference37 articles.

1. Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D, On behalf of the ESMO Guidelines Committee clinicalguidelines@esmo org. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann Oncol. 2016;27:50–7.

2. Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS SSO and TOS. Ann Oncol. 2019;30:34–43.

3. Ajani JA, D Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, et al. NCCN Guidelines Version 3.2020 Gastric Cancer [Internet]. 2020.

4. Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guzmán M, Custodio AB, et al. SEOM clinical guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016;18:1179–86.

5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 study group. J Clin Oncol. 2006;24:4991–7.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry;Clinical and Translational Oncology;2024-02-15

2. Textbook Outcome after Gastrectomy for Gastric Cancer Is Associated with Improved Overall and Disease-Free Survival;Journal of Clinical Medicine;2023-08-21

3. Patients with esophageal adenocarcinoma showed better prognosis than those with adenocarcinoma of the gastroesophageal junction;Journal of Digestive Diseases;2023-02

4. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy;Therapeutic Advances in Medical Oncology;2023-01

5. Relationships among microbiota, gastric cancer, and immunotherapy;Frontiers in Microbiology;2022-09-12